Overview

Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
Phase:
Phase 3
Details
Lead Sponsor:
Lipocine Inc.
Collaborators:
INC Research
PPD
Syneos Health
Treatments:
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones, Hormone Substitutes, and Hormone Antagonists
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate